NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Anbio Biotechnology
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026
$3.27+0.14 (+4.47%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 22.2
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2021 to 2025
Gross margin
87.2%
Operating margin
66.7%
Net margin
74.1%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.6% | -28.4% | – | – | |
| Gross profit | +28.2% | -15.6% | – | – | |
| Operating income | +189.1% | -17.3% | – | – | |
| Net income | +169.9% | -13.8% | – | – | |
| EPS, diluted | +162.5% | -98.9% | – | – |
Returns and balance sheet
5 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2021 | FY2021 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 27.0% | |
| Return on assets | – | – | 26.0% | |
| Current ratio | – | – | 344.31 | |
| Diluted shares | – | – | 44M |
Cash use needs five years of cash flow figures
Anbio Biotechnology does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin74.1%
×Asset turnover0.35×
×Equity multiplier1.04×
=Return on equity, FY202527.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 74.1% | 0.35× | 1.04× | 27.0% |
| FY2024 | 29.0% | 0.47× | 1.09× | 14.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$6.40M
- Cash generatingOperating cash flow above zero-$6.74M
- Return on assets improvedROA up on the prior year15.0% → 33.8%
- Earnings backed by cashOperating cash flow above net income-$6.74M vs $6.40M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose10.71 → 344.31
- No dilutionShare count did not rise42M → 44M
- Gross margin improvedGross margin up on the prior year71.90% → 87.24%
- More efficientAsset turnover rose0.52 → 0.46